Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.
The new Fast Track designation is for the treatment of advanced or metastatic breastcancer in patients with human epidermal growth factor receptor 2 (HER2) low (IHC 1+ or IHC 2+/ISH–) or HER2 ...
To gain insights into treatmentoptions available internationally ... effectively target and destroy cancer cells. These therapies have been game-changers for advanced cancers, including ...
Some results have been hidden because they may be inaccessible to you